Cargando…

MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials

INTRODUCTION: Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymet...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Christopher S., Brown, Melanie R., Adams, Dee, Cassity, Marca, Sevelius, Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589439/
https://www.ncbi.nlm.nih.gov/pubmed/36299539
http://dx.doi.org/10.3389/fpsyt.2022.932605
_version_ 1784814305806385152
author Stauffer, Christopher S.
Brown, Melanie R.
Adams, Dee
Cassity, Marca
Sevelius, Jae
author_facet Stauffer, Christopher S.
Brown, Melanie R.
Adams, Dee
Cassity, Marca
Sevelius, Jae
author_sort Stauffer, Christopher S.
collection PubMed
description INTRODUCTION: Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the treatment of PTSD. Issues related to equitable access, power imbalances in the therapeutic relationship, and vulnerable states of consciousness occasioned by MDMA are magnified when working with people affected by structural vulnerabilities and health disparities, and community engagement in research planning and implementation is essential. To inform the inclusion and safety of TGD people in future MDMA-assisted psychotherapy research, the aims of the current study were to: characterize TGD experiences with trauma-related mental health care, assess openness of TGD people to participate in experimental PTSD research, and to gather specific feedback on protocol design for conducting MDMA-assisted psychotherapy with TGD people. MATERIALS AND METHODS: We conducted three virtual focus group discussions (FGDs) with 5–6 participants each (N = 17). Eligible TGD participants had a history of receiving trauma-related mental health care. Each FGD was facilitated by two licensed clinicians who identified as TGD. Qualitative data analysis was conducted via an iterative process of identification of recurrent patterns and themes. RESULTS: We have identified several key issues TGD people face when seeking and engaging in trauma-related mental health care, including barriers to receiving adequate gender-affirming and trauma-informed mental health care and frustration with providers lacking cultural humility. Suggested amendments to MDMA-assisted psychotherapy protocols include: routine collection of trans-inclusive gender identity data, implementing an explicit gender-affirming treatment approach, ensuring a culturally safe setting, and diversifying co-therapy dyads. DISCUSSION: The inclusion of TGD voices in early conversations about emerging experimental PTSD interventions promotes equitable access, in the context of health and healthcare disparities, and helps researchers understand the needs of the community and tailor research to meet those needs. Through an ongoing conversation with the TGD community, we aim to incorporate a gender-affirming approach into existing research protocols and inform future applications of MDMA-assisted psychotherapy in addressing the effects of minority stress and boosting resilience.
format Online
Article
Text
id pubmed-9589439
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95894392022-10-25 MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials Stauffer, Christopher S. Brown, Melanie R. Adams, Dee Cassity, Marca Sevelius, Jae Front Psychiatry Psychiatry INTRODUCTION: Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the treatment of PTSD. Issues related to equitable access, power imbalances in the therapeutic relationship, and vulnerable states of consciousness occasioned by MDMA are magnified when working with people affected by structural vulnerabilities and health disparities, and community engagement in research planning and implementation is essential. To inform the inclusion and safety of TGD people in future MDMA-assisted psychotherapy research, the aims of the current study were to: characterize TGD experiences with trauma-related mental health care, assess openness of TGD people to participate in experimental PTSD research, and to gather specific feedback on protocol design for conducting MDMA-assisted psychotherapy with TGD people. MATERIALS AND METHODS: We conducted three virtual focus group discussions (FGDs) with 5–6 participants each (N = 17). Eligible TGD participants had a history of receiving trauma-related mental health care. Each FGD was facilitated by two licensed clinicians who identified as TGD. Qualitative data analysis was conducted via an iterative process of identification of recurrent patterns and themes. RESULTS: We have identified several key issues TGD people face when seeking and engaging in trauma-related mental health care, including barriers to receiving adequate gender-affirming and trauma-informed mental health care and frustration with providers lacking cultural humility. Suggested amendments to MDMA-assisted psychotherapy protocols include: routine collection of trans-inclusive gender identity data, implementing an explicit gender-affirming treatment approach, ensuring a culturally safe setting, and diversifying co-therapy dyads. DISCUSSION: The inclusion of TGD voices in early conversations about emerging experimental PTSD interventions promotes equitable access, in the context of health and healthcare disparities, and helps researchers understand the needs of the community and tailor research to meet those needs. Through an ongoing conversation with the TGD community, we aim to incorporate a gender-affirming approach into existing research protocols and inform future applications of MDMA-assisted psychotherapy in addressing the effects of minority stress and boosting resilience. Frontiers Media S.A. 2022-10-10 /pmc/articles/PMC9589439/ /pubmed/36299539 http://dx.doi.org/10.3389/fpsyt.2022.932605 Text en Copyright © 2022 Stauffer, Brown, Adams, Cassity and Sevelius. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Stauffer, Christopher S.
Brown, Melanie R.
Adams, Dee
Cassity, Marca
Sevelius, Jae
MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
title MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
title_full MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
title_fullStr MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
title_full_unstemmed MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
title_short MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials
title_sort mdma-assisted psychotherapy; inclusion of transgender and gender diverse people in the frontiers of ptsd treatment trials
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589439/
https://www.ncbi.nlm.nih.gov/pubmed/36299539
http://dx.doi.org/10.3389/fpsyt.2022.932605
work_keys_str_mv AT staufferchristophers mdmaassistedpsychotherapyinclusionoftransgenderandgenderdiversepeopleinthefrontiersofptsdtreatmenttrials
AT brownmelanier mdmaassistedpsychotherapyinclusionoftransgenderandgenderdiversepeopleinthefrontiersofptsdtreatmenttrials
AT adamsdee mdmaassistedpsychotherapyinclusionoftransgenderandgenderdiversepeopleinthefrontiersofptsdtreatmenttrials
AT cassitymarca mdmaassistedpsychotherapyinclusionoftransgenderandgenderdiversepeopleinthefrontiersofptsdtreatmenttrials
AT seveliusjae mdmaassistedpsychotherapyinclusionoftransgenderandgenderdiversepeopleinthefrontiersofptsdtreatmenttrials